Alzheimer's disease can remain undetected until it is too late to treat. Large-scale screening programs could help to detect early-stage disease, but current diagnostic methods are too cumbersome and expensive. Could a simple urine test reveal if someone has early-stage Alzheimer's disease and could this pave the way for large-scale screening programs?
A new study published to Frontiers is the first to identify formic acid as a sensitive urinary biomarker that can reveal early-stage Alzheimer's disease, potentially paving the way for inexpensive and convenient disease screening.
Reference:
Biomarker in urine could be the first to reveal early-stage Alzheimer's disease; Frontiers in Aging Neuroscience, DOI:10.3389/fnagi.2022.1046066.
Zika-exposed children may display neurodevelopmental differences
Children who are exposed to the Zika virus while in the womb, but who are not subsequently diagnosed with Zika-related birth defects and congenital Zika syndrome (CZS), may still display differences in some aspects of cognitive development, mood and mobility compared to unexposed children, reports a study published in Pediatric Research. These findings suggest that Zika-exposed children may need some additional support and monitoring as they get older.
There are still many unanswered questions about the long-term impacts of Zika on children exposed in utero. These findings are another piece of the puzzle that provides insight into the long-term neurodevelopment of children with prenatal Zika virus exposure.
Reference:
Zika-exposed children may display neurodevelopmental differences; JOURNAL- Pediatric Research.
New single-dose treatment for sleeping sickness could help eliminate transmission of the disease by 2030
Sleeping sickness, or human African trypanosomiasis (HAT), is a neglected tropical disease, which can be fatal if left untreated.
A new, single-dose, oral treatment for sleeping sickness is as effective as current treatments and could be a key factor in eliminating disease transmission by 2030, suggests a new study published in The Lancet Infectious Diseases. The study finds that a single oral dose of the drug acoziborole is 95% effective 18 months after treatment in treating sleeping sickness in adults and adolescents, regardless of disease stage.
During the study, they recruited patients from 10 hospitals. A single 960 mg oral dose of acoziborole was administered to 208 patients; 167 diagnosed with late-stage human African trypanosomiasis. The patients were followed up for 18 months to see if treatment was successful.
Reference:
THE LANCET INFECTIOUS DISEASES: New single-dose treatment for sleeping sickness could hel eliminate transmission of the disease by 2030
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.